Evidence map›Paper›PMID 27601049›Full record

ArticleMammalian genome : official journal of the International Mammalian Genome Society2016

Deregulation of the Hippo pathway in mouse mammary stem cells promotes mammary tumorigenesis.

Hongbin Li, Barry M Gumbiner

Open access · greenAbstract read
In one paragraph

Article in Mammalian genome : official journal of the International Mammalian Genome Society, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Is cell migration a selectable trait in the natural evolution of cancer development?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2019
    Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hongbin LiDepartment of Cell Biology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Barry M GumbinerDepartment of Cell Biology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA. gumbiner@uw.edu.
University of Virginia · US

Funding

Women's Oncology Program - WONP30CA044579 · NCI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Thomas P. Loughran · 1987 to 2026
$72.1M
Cadherin-catenin Mediated Contact Inhibition of Cell GrowthR01GM098615 · NIGMS · UNIVERSITY OF VIRGINIA · PI GUMBINER, BARRY M. · 2011 to 2014
$2.1M
NCI NIH HHS P30 CA044579NIGMS NIH HHS R01 GM098615
6 · The paper itself

Abstract

The Hippo-YAP pathway mediates organ size control, contact inhibition, and tumorigenesis. It is a kinase cascade that inhibits the nuclear localization and transcriptional activities of YAP and TAZ. E-cadherin, cell junctions, polarity proteins, and the merlin/NF2 tumor suppressor activate the pathway to inhibit YAP/TAZ activity, while growth factor signaling inhibits the pathway to activate YAP/TAZ in the nucleus. We examined its role in the development of mouse mammary glands and tumor formation using gland reconstitution by transplantation of genetically modified mammary stem cells (MaSCs). Knockdown of YAP and TAZ with shRNA in MaSCs did not inhibit gland reconstitution. In contrast, knockdown of β-catenin blocked gland reconstitution, consistent with the known role of Wnt signaling in mammary gland development. However, we find that Hippo signaling is involved in mammary tumor formation. Expression of a constitutively active form of YAP caused rapid formation of large tumors. Moreover, knockdown of YAP/TAZ slowed the development of tumors in polyoma middle T transgenic mice, a well-studied mammary tumor model involving activation of several signaling pathways. YAP accumulated in nuclei of mammary glands in ErbB2/EGFR-transgenic mice, suggesting that EGFR signaling affects YAP in vivo similar to cell culture. ErbB2/EGFR-transgenic mice develop mammary tumors in 7-8 months, but surprisingly, MaSCs from these mice did not form tumors when transplanted into host mice. Nonetheless, expression of dominant-negative Lats, which inhibits Hippo signaling, leads to tumor formation in ErbB2-transgenic mice, suggesting that Hippo signaling is involved in EGFR-induced mammary tumorigenesis.

Indexed as

AcyltransferasesAdaptor Proteins, Signal TransducingAnimalsbeta CateninBreast NeoplasmsCarcinogenesisCell Cycle ProteinsErb-b2 Receptor Tyrosine KinasesErbB ReceptorsFemaleHippo Signaling PathwayHumansMammary Glands, AnimalMiceMice, TransgenicNeoplastic Stem CellsAcyltransferasesAdaptor Proteins, Signal Transducingbeta CateninCell Cycle ProteinsEGFR protein, mouseErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesErbB ReceptorsLats1 protein, mousePhosphoproteinsProtein Serine-Threonine KinasesRNA, Small Interferingtafazzin protein, mouseTranscription FactorsYap1 protein, mouseYAP-Signaling Proteins

Identifiers

PMID27601049
PMCPMC5112122
OpenAlexW2518461346

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.